Dados B3 › VSTE3 × AMER3
VSTE3 × AMER3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | VSTE3 | AMER3 | year |
|---|---|---|---|
| ROE | 0.0% | -5.6% | 2025 |
| ROIC | 6.4% | 3.4% | 2025 |
| ROA | 1.5% | -1.6% | 2025 |
| Gross margin | 63.7% | 27.0% | 2025 |
| EBIT margin | 6.9% | 2.7% | 2025 |
| Net margin | 2.0% | -2.2% | 2025 |
| Net debt/EBITDA | 1.05x | 0.83x | 2025 |
| Current ratio | 1.53x | 1.67x | 2025 |
| Revenue growth (1y) | 10.7% | -1.2% | 2025 |
| Revenue growth (5y CAGR) | 15.5% | 4.0% | 2025 |
| Piotroski F-Score | 8/9 | 3/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | VSTE3 | AMER3 | year |
|---|---|---|---|
| P/E | — | -3.81x | 2025 |
| P/B | 0.42x | 0.22x | 2025 |
| EV/EBITDA | 2.75x | 1.73x | 2025 |
| FCF yield | 22.1% | 34.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 14:50 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.